MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma Clinical Trial

Official title:

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02514824
• Other study ID #: 15-223
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 2015
• Est. completion date: June 2017

Study information

• Verified date: December 2020
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. - The name of the study intervention involved in this study is: MLN0128.

Description:

This is a phase I/II clinical trial. A phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has not approved MLN0128 as a treatment for any disease. MLN0128 may prevent tumor cells from dividing and growing by selectively and potently inhibiting a chemical, mTOR kinase, which regulates cell growth and survival. Patients with merkel cell carcinoma have been observed to sometimes carry genetic alterations in their tumor cells which may make the cancer more sensitive to inhibition by MLN0128. In this research study,the investigators are studying the usefulness of MLN0128 in merkel cell carcinoma cases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: June 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Metastatic or recurrent MCC confirmed by histology
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan (see section 10 for the evaluation of measureable disease). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented
• Age 18 years or older
• ECOG performance status = 2
• Participants must have normal organ and marrow function
• Female patients who:
• Are postmenopausal for at least 1 year before the screening visit --- OR
• Are surgically sterile --- OR
• If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time
• Male patients, even if surgically sterilized (ie, status post-vasectomy), who:
• Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or
• Agree to completely abstain from heterosexual intercourse
• Treatment with strong CYP2C19, CYP3A4, and CYP2C9 inhibitors and/or inducers
• Tissue for correlative studies must be available (paraffinized or frozen)
• Ability to swallow oral medications and maintain an empty stomach state for 2 hours prior to the MLN0128 dose and for 1 hour following administration
• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

• Participants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
• The subject has active brain metastases or epidural disease
• Participants who are receiving any other investigational agents within 14 days before the first dose of study drug
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
• Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug
• Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128
• Poorly controlled diabetes mellitus
• History of any of the following within the last 6 months prior to study entry:
• Ischemic myocardial event
• Ischemic cerebrovascular event
• Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia
• Placement of a pacemaker for control of rhythm
• New York Heart Association (NYHA) Class III or IV heart failure
• Pulmonary embolism
• Significant active cardiovascular or pulmonary disease at the time of study entry,

including:

• Uncontrolled high blood pressure
• Pulmonary hypertension
• Uncontrolled asthma
• Significant valvular disease; severe regurgitation or stenosis
• Medically significant (symptomatic) bradycardia
• History of arrhythmia requiring an implantable cardiac defibrillator
• Baseline prolongation of the rate-corrected QT interval (QTc)
• Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Merkel Cell
• Merkel Cell Carcinoma

Intervention

Drug:
• MLN0128
Investigational mTOR kinase inhibitor

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MLN01283 Maximum Tolerated Dose (MTD) [Phase I]	The MLN01283 MTD is determined by the number of participants who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached but the highest dose received may be the Recommended Phase II Dose (RP2D).	The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
Primary	Dose Limiting Toxicity (DLT) [Phase I]	A DLT was defined as an adverse event (AE) assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications meets any of the following criteria including but not limited to: grade (G) 4-5 AEs, G3 thrombocytopenia, neutropenia, AST, ALT, serum creatinine or total bilirubin 2 to 3 x upper limit normal (ULN), aymptomatic amylase and/or lipase lasting >7 consecutive days; febrile neutropenia; G3 cardiac, hyperglycemia, mood alteration; G2 pancreatitis; G2 hyperglycemia unresolved within 14 days; G2 mood alteration unresolved in 14 days despite medical treatment; Dose interruption >21 days due to G2 dematologic; one grade level increase neurotoxicity.	The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.